Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL)
Galaverna F, Ruggeri A, Merli P, Kapoor N, Agarwal-Hashmi R, Aquino V, Jacobsohn D, Qasim W, Nemecek E, Krishnamurti L, Manwani D, Kuhn M, Locatelli F, Naik S. Administration of BPX-501 Cells Following Αβ T and B-Cell-Depleted HLA Haploidentical HSCT (haplo-HSCT) in Children with Acute Leukemias (AL). Transplantation And Cellular Therapy 2019, 25: s15-s16. DOI: 10.1016/j.bbmt.2018.12.082.Peer-Reviewed Original ResearchSteroid-resistant GVHDAcute leukemiaEvaluable ptsEfficacy outcomesΑβ TT cellsB cellsPediatric ptsBetter overall clinical responsePost-transplant GvHD prophylaxisHigh-risk acute leukemiaHLA-haploidentical HSCTOverall clinical responseSubset of ptsPrimary graft failureTumor-specific immunityHost disease symptomsInducible caspase-9 safety switchAllogeneic HSCTEnhanced graftGVHD prophylaxisHaplo-HSCTHaploidentical HSCTLeukemic effectsPlatelet engraftment